Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 8/20 | 0.69 |
| ▸ | PYGM | P11217 | 6/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.50 |
| ▸ | CCKAR | P32238 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11959858 | 1.00 | PYGL (0.69) | PYGLPYGMRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL25329367 | 0.82 | PYGL (0.64) | PYGLPYGMRIPK1 | |
| SCHEMBL29900499 | 0.82 | PYGL (0.64) | PYGLPYGMRIPK1 | |
| SCHEMBL15541576 | 0.82 | PYGL (0.64) | PYGLPYGMRIPK1 | |
| SCHEMBL2837105 | 0.81 | PYGL (0.60) | PYGLPYGMRIPK1 | |
| SCHEMBL11959861 | 0.79 | PYGL (0.47) | PYGLPYGMRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL8916040 | 0.79 | PYGL (0.47) | PYGLPYGMRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL651278 | 0.75 | EPHX2 (0.63) | PYGLPYGMCCKARCCKBR | |
| SCHEMBL29900496 | 0.75 | EPHX2 (0.63) | PYGLPYGMCCKARCCKBR | |
| SCHEMBL4806148 | 0.75 | EPHX2 (0.63) | PYGLPYGMCCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| WO-2007066784-A2 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | PYGL 2351/4885PYGM 2334/4885RAB9A 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.